Prognostic value of perfusion MR imaging in patients with oligodendroglioma: A survival study.

Zhen Jiang 1 Jean-François Le Bas 2, * Sylvie Grand 3 Caroline Salon 4 Caroline Pasteris 5 Dominique Hoffmann 6 Fabrice Bing 7 François Berger 8 Stephan Chabardes 9 C. Liu 10, 11 Alexandre Krainik 3
* Auteur correspondant
1 INSERM U836, équipe 5, Neuro-imagerie fonctionnelle et métabolique
RBCH - RMN biomédicale : de la cellule à l'homme, GIN - Grenoble Institut des Neurosciences, Service de neuro-radiologie et IRM, 2nd affiliated Hospital od Soochow University
2 INSERM U836, équipe 6, Rayonnement synchrotron et recherche médicale
RBCH - RMN biomédicale : de la cellule à l'homme, GIN - Grenoble Institut des Neurosciences, Service de neuro-radiologie et IRM
3 INSERM U836, équipe 5, Neuro-imagerie fonctionnelle et métabolique
GIN - Grenoble Institut des Neurosciences, Service de neuro-radiologie et IRM
8 INSERM U836, équipe 7, Nanomédecine et cerveau
GIN - Grenoble Institut des Neurosciences, Département de Neuro-oncologie
Abstract : OBJECTIVE: The purpose of this study was to evaluate retrospectively whether cerebral blood volume measurement based on pretreatment perfusion MRI is a prognostic biomarker for survival in patients with oligodendroglioma or mixed oligoastrocytoma. PATIENTS AND METHODS: Between 1998 and 2004, 54 patients (23 females and 31 males), aged 21-73 years, with oligodendroglioma (or mixed tumour) were examined prior to beginning treatment with dynamic susceptibility-weighted contrast (DSC) perfusion MRI during gadolinium first-pass. The relative cerebral blood volume (rCBV) was calculated by dividing the measurement within the tumour by the measurement of the normal-appearing contralateral region. Patients were classified in two groups, grade A and grade B, according to the Saint-Anne Hospital classification and followed-up clinically and by means of MRI until their death or for a minimum of 5 years. Patients were also classified in grade II and grade III-IV, according to the World Health Organisation (WHO) classification, and were analysed with the same methods. Age, sex, treatment, tumour grade, contrast agent uptake, and rCBV were tested using survival curves with Kaplan-Meier's method, and their differences were analysed using the log-rank test. RESULTS: In this population, median survival was 3 years. A rCBV threshold value of 2.2 was validated as a prognostic factor, for survival in these patients with oligodendrogliomas. Age, sex, contrast uptake, and maximum rCBV were found to be prognostic factors in univariate analysis. Multivariate analysis revealed that tumour grade (grade A/grade B), rCBV, age, and sex were prognostic factors independent of the other factors. The tumour grade according to the WHO classification (II versus III-IV) was also detected as an independent prognostic factor. CONCLUSION: Pretreatment rCBV measured by DSC perfusion MRI was found to be a prognostic factor for survival in patients with oligodendroglioma or mixed tumour, by using the Saint-Anne Hospital classification, which separate the IIB from the IIA.
Type de document :
Article dans une revue
Journal de Neuroradiologie / Journal of Neuroradiology, Elsevier Masson, 2011, 38 (1), pp.53-61. 〈10.1016/j.neurad.2010.03.004〉
Liste complète des métadonnées

Littérature citée [26 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00498533
Contributeur : Michel Dojat <>
Soumis le : mercredi 11 janvier 2012 - 15:20:12
Dernière modification le : jeudi 1 février 2018 - 01:11:39
Document(s) archivé(s) le : mardi 13 décembre 2016 - 17:10:17

Fichier

 Accès restreint
Fichier visible le : jamais

Connectez-vous pour demander l'accès au fichier

Identifiants

Collections

U836 | UGA

Citation

Zhen Jiang, Jean-François Le Bas, Sylvie Grand, Caroline Salon, Caroline Pasteris, et al.. Prognostic value of perfusion MR imaging in patients with oligodendroglioma: A survival study.. Journal de Neuroradiologie / Journal of Neuroradiology, Elsevier Masson, 2011, 38 (1), pp.53-61. 〈10.1016/j.neurad.2010.03.004〉. 〈inserm-00498533〉

Partager

Métriques

Consultations de la notice

215